Christopher Hulme

Iluminos Therapeutics, LLC

NIH Rank #4399
  • R01 Holder
  • Early Career

NIH Funding · FY2024

Total Funding
$2.2M
Fiscal year 2024
Grants Awarded
2
Active NIH grants
National Rank
#4,399
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $2.2M across 2 grants · National rank #4399.

Top grants by award amount

Christopher Hulme's NIH grant portfolio, ranked by award amount.

  • 4R44NS129400-02R44
    Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome
    $1.5M
    award amount
  • 5R01AG067926-05R01
    DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease
    $736.6K
    award amount

Affiliations

Institutions that have administered grants for Christopher Hulme.

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    Iluminos Therapeutics, LLC
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #4399
  6. 2024
    Entered Top 25% Nationally
    Ranked #4399
  7. 2024
    Multi-Institutional Research
    Awards at 2 institutions

Related investigators

Other NIH-funded PIs frequently associated with Christopher Hulme.